BriaCell Therapeutics (BCTX) said Friday it priced a public offering of 3.07 million units at $4.50 each, to raise gross proceeds of about $13.8 million.
Each unit includes one common share and one warrant to buy another share at $5.25, exercisable immediately and valid for five years, the company said.
The warrants will begin trading on Nasdaq under the ticker "BCTXZ" on Friday, the company said, adding the offering is expected to close on Monday, with proceeds going toward working capital and general corporate purposes.
BriaCell shares were down more than 21% in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.